Courtagen added the nucSEEK® Focus Nuclear Mitochondrial Gene Panel and epiSEEK® Focus Epilepsy and Seizure Disorder Panel to the company’s test offerings. The new tests will complement the current nucSEEK® Comprehensive Nuclear Mitochondrial Exome Panel and epiSEEK® Comprehensive Epilepsy and Seizure Disorder Panel, respectively. Physicians will now have more flexibility to choose the most appropriate test for their patient.

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx™ test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza™ (olaparib). Lynparza is a PARP (poly-ADP ribose polymerase) inhibitor being developed by AstraZeneca.

Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the release of a new genetic test, lysoSEEK™, which is focused on early identification of genes associated with potentially treatable lysosomal storage disorders.

EMPATHY-P showed that Prolaris provides valuable clinical information that can help physicians improve healthcare and outcomes for their patients with early prostate cancer,” said Colin Hayward, M.D., European medical director, Myriad. “There is no one-size-fits-all treatment approach in prostate cancer. Prolaris provides objective genetic information to help clinicians tailor treatment plans based on patients’ individual risk profiles.

A whole-genome sequencing study of families with multiple children with autism spectrum disorder has found that siblings often don’t share ASD-related mutations, the researchers say in Nature Genetics.